The United Kingdom, which was the first to grant authorization to the vaccine developed by Pfizer and Moderna, is expected to give the green light to the vaccine developed by AstraZeneca and Oxford University this week.

The global tally of confirmed coronavirus cases hit 60 million on Nov. 25, with the pace of new infections accelerating and the United States reporting record numbers of hospitalizations, according to a Reuters tally.

Britain will host clinical trials where volunteers are deliberately infected with the new coronavirus to test the effectiveness of vaccine candidates, the Financial Times reported, citing people involved in the project.

GlaxoSmithKline opened a new $13 million research hub in London focused on artificial intelligence.

U.S.-based Merck is moving ahead with the company’s $1.3 billion research center in London.

Greater Than One announced the opening of a new office in London, known as GTO Global, to bolster the company’s partnerships with marketers in the region.

The United Kingdom’s COVID-19 death toll exceeds 40,000, by far the worst yet reported in Europe, raising more questions about Prime Minister Boris Johnson’s handling of the coronavirus crisis.

Vertex Pharmaceuticals Inc. priced the company’s FDA-approved Trikafta, a three-drug combination for cystic fibrosis, at $311,503 per year.

Novartis AG’s gene therapy Luxturna for blindness is recommended for use on England’s public health service, according to the country’s healthcare cost-effectiveness watchdog NICE.

Opioid use has reached crisis proportions not only in the United States but also in Canada and some European countries, as prescription opioid painkillers have become much more common, the OECD club of wealthy nations said.